News
3d
GlobalData on MSNGSK acquires efimosfermin alfa from Boston Pharma for $2bnGSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...
London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...
Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...
GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...
LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...
Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic ...
Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver ...
Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...
Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results